Member Contact: Dr Tara Karnezis
Position: CEO & Managing Director
Industry: Biotech & Pharmaceuticals
Gertrude Biomedical is a private, early-stage drug discovery and development company based at the Bio21 Institute in Parkville, Melbourne. The company is developing small molecule inhibitors to SOX18, a transcription factor target which regulates gene pathways to manipulate cell growth/differentiation, inflammation and angiogenesis.
Gertrude Biomedical is focused on developing drugs to treat two indications of significant unmet need, Kaposi Sarcoma and Angiosarcoma, however, the multi-functional nature of SOX18 translates to significant commercial and clinical potential beyond orphan indications.